Literature DB >> 25506722

Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in African Americans.

Albert M Levin1,2, Indra Adrianto3, Indrani Datta1,2, Michael C Iannuzzi4, Sheri Trudeau1, Jia Li1,2, Wonder P Drake5, Courtney G Montgomery3, Benjamin A Rybicki1.   

Abstract

HLA-DRB1 is a sarcoidosis risk gene, and the *03:01 allele is strongly associated with disease resolution in European sarcoidosis cases. Whereas the HLA-DRB1 variation is associated with sarcoidosis susceptibility in African Americans, DRB1 risk alleles are not as well defined, and associations with disease resolution have not been studied. Associations between genotyped and imputed HLA-DRB1 alleles and disease susceptibility/resolution were evaluated in a sample of 1,277 African-American patients with sarcoidosis and 1,467 control subjects. In silico binding assays were performed to assess the functional significance of the associated alleles. Increased disease susceptibility was associated with the HLA-DRB1 alleles *12:01 (odds ratio [OR], 2.11; 95% confidence interval [CI], 1.65-2.69; P = 3.2 × 10(-9)) and *11:01 (OR, 1.69; 95% CI, 1.42-2.01; P = 3.0 × 10(-9)). The strongest protective association was found with *03:01 (OR, 0.56; 95% CI, 0.44-0.73; P = 1.0 × 10(-5)). The African-derived allele *03:02 was associated with decreased risk of persistent radiographic disease (OR, 0.52; 95% CI, 0.37-0.72; P = 1.3 × 10(-4)), a finding consistent across the three component studies comprising the analytic sample. The DRB1*03:01 association with disease persistence was dependent upon local ancestry, with carriers of at least one European allele at DRB1 at a decreased risk of persistent disease (OR, 0.36; 95% CI, 0.14-0.94; P = 0.037). Results of in silico binding analyses showed that DRB1*03:01 consistently demonstrated the highest binding affinities for six bacterial peptides previously found in sarcoidosis granulomas, whereas *12:01 displayed the lowest binding affinities. This study has identified DRB1*03:01 and *03:02 as novel alleles associated with disease susceptibility and course in African Americans. Further investigation of DRB1*03 alleles may uncover immunologic factors that favor sarcoidosis protection and resolution among African Americans.

Entities:  

Keywords:  HLA-DRB1 chains; SNPs; association studies; genetic; molecular docking simulation; pulmonary sarcoidosis

Mesh:

Substances:

Year:  2015        PMID: 25506722      PMCID: PMC4566045          DOI: 10.1165/rcmb.2014-0227OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  58 in total

1.  Estimating local ancestry in admixed populations.

Authors:  Sriram Sankararaman; Srinath Sridhar; Gad Kimmel; Eran Halperin
Journal:  Am J Hum Genet       Date:  2008-02       Impact factor: 11.025

2.  HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis.

Authors:  K Bogunia-Kubik; J Tomeczko; K Suchnicki; A Lange
Journal:  Tissue Antigens       Date:  2001-01

3.  Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis.

Authors:  P J Foley; D S McGrath; E Puscinska; M Petrek; V Kolek; J Drabek; P A Lympany; P Pantelidis; K I Welsh; J Zielinski; R M du Bois
Journal:  Am J Respir Cell Mol Biol       Date:  2001-09       Impact factor: 6.914

4.  Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans.

Authors:  Michael C Iannuzzi; Mary J Maliarik; Laila M Poisson; Benjamin A Rybicki
Journal:  Am J Respir Crit Care Med       Date:  2003-02-13       Impact factor: 21.405

5.  Human leukocyte antigen-DR alleles influence the clinical course of pulmonary sarcoidosis in Asian Indians.

Authors:  Surendra K Sharma; Arumugam Balamurugan; Ravindra M Pandey; Pradip Kumar Saha; Narinder K Mehra
Journal:  Am J Respir Cell Mol Biol       Date:  2003-02-14       Impact factor: 6.914

6.  Löfgren's syndrome: human leukocyte antigen strongly influences the disease course.

Authors:  Johan Grunewald; Anders Eklund
Journal:  Am J Respir Crit Care Med       Date:  2008-11-07       Impact factor: 21.405

Review 7.  Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions.

Authors:  Giuseppina Candore; Domenico Lio; Giuseppina Colonna Romano; Calogero Caruso
Journal:  Autoimmun Rev       Date:  2002-02       Impact factor: 9.754

8.  M. avium binding to HLA-DR expressed alleles in silico: a model of phenotypic susceptibility to sarcoidosis.

Authors:  C Saltini; M Pallante; E Puxeddu; S Contini; C E Voorter; M Drent; M Amicosante
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2008-12       Impact factor: 0.670

9.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis.

Authors:  Soumya Raychaudhuri; Cynthia Sandor; Eli A Stahl; Jan Freudenberg; Hye-Soon Lee; Xiaoming Jia; Lars Alfredsson; Leonid Padyukov; Lars Klareskog; Jane Worthington; Katherine A Siminovitch; Sang-Cheol Bae; Robert M Plenge; Peter K Gregersen; Paul I W de Bakker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330

10.  Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan.

Authors:  Morten Nielsen; Claus Lundegaard; Thomas Blicher; Bjoern Peters; Alessandro Sette; Sune Justesen; Søren Buus; Ole Lund
Journal:  PLoS Comput Biol       Date:  2008-07-04       Impact factor: 4.475

View more
  13 in total

1.  Solving the Conundrum: Immunogenetics of Sarcoidosis.

Authors:  Naftali Kaminski; Wonder P Drake
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

Review 2.  Distinguishing Blau Syndrome from Systemic Sarcoidosis.

Authors:  Katherine P Kaufman; Mara L Becker
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

Review 3.  Granuloma genes in sarcoidosis: what is new?

Authors:  Annegret Fischer; Benjamin A Rybicki
Journal:  Curr Opin Pulm Med       Date:  2015-09       Impact factor: 3.155

Review 4.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

5.  HLA class II variants defined by next generation sequencing are associated with sarcoidosis in Korean patients.

Authors:  Kateřina Sikorová; Su-Jin Moon; Hee-Young Yoon; Adam Strnad; Jin Woo Song; Martin Petrek
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

Review 6.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

Review 7.  In-silico modeling of granulomatous diseases.

Authors:  Elliott D Crouser
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

8.  Genome-Wide Association Study of Ocular Sarcoidosis Confirms HLA Associations and Implicates Barrier Function and Autoimmunity in African Americans.

Authors:  Lori Garman; Nathan Pezant; Ambra Pastori; Kathryn A Savoy; Chuang Li; Albert M Levin; Michael C Iannuzzi; Benjamin A Rybicki; Indra Adrianto; Courtney G Montgomery
Journal:  Ocul Immunol Inflamm       Date:  2020-03-06       Impact factor: 3.070

9.  Methotrexate treatment efficacy in sarcoidosis might be related to TNF-α polymorphism: real life preliminary study.

Authors:  Anna Goljan Geremek; Elzbieta Puscinska; Monika Czystowska; Agnieszka Skoczylas; Michal Bednarek; Adam Nowinski; Dorota Gorecka; Urszula Demkow; Pawel Sliwinski
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

10.  Genetic Variants Associated with FDNY WTC-Related Sarcoidosis.

Authors:  Krystal L Cleven; Kenny Ye; Rachel Zeig-Owens; Kerry M Hena; Cristina Montagna; Jidong Shan; H Dean Hosgood; Nadia Jaber; Michael D Weiden; Hilary L Colbeth; David G Goldfarb; Simon D Spivack; David J Prezant
Journal:  Int J Environ Res Public Health       Date:  2019-05-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.